Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD

Crohn's Disease Clinical Trial

Official title:

A Phase 3b, Randomized, Controlled, Multicentre Study With Oral Ferric Maltol (Feraccru) or Intravenous Iron (Ferric Carboxy Maltose; FCM), for the Treatment of Iron Deficiency Anaemia in Subjects With Inflammatory Bowel Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02680756
• Other study ID #: ST10-01-304
• Status: Completed
• Phase: Phase 3
• Start date: January 2016
• Est. completion date: January 2019

Study information

• Verified date: October 2020
• Source: Shield Therapeutics
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to compare the efficacy of ferric maltol and intravenous iron (IVI) Ferric Carboxy Maltose in the treatment of iron deficiency anaemia (IDA) and subsequent maintenance of haemoglobin in subjects with Inflammatory Bowel Disease (IBD).

Description:

A phase 3b, randomized, controlled, multicentre study with oral ferric maltol or intravenous iron (FCM), for the treatment of iron deficiency anaemia in subjects with inflammatory bowel disease.

Approximately 242 eligible subjects will be randomised (1:1) to receive one of the following treatments for the duration of the study treatment period (52 weeks):

• Oral ferric maltol, 30 mg capsule bid.

• Intravenous iron (ferric carboxy maltose) as per SPC

In the FCM arm IV iron treatment will be repeated if the subject is iron deficient at any of the study visits.

Subject participation in the study will consist of 3 periods:

• Screening: Up to 14 days

• Randomised Treatment: 52 weeks

• Post-treatment safety follow-up: 14 days after study medication discontinuation

Primary efficacy and safety of ferric maltol and Intravenous iron (ferric carboxy maltose) will be evaluated after the first 12 weeks.

End of study evaluations will occur at Week 52 or premature discontinuation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 250
• Est. completion date: January 2019
• Est. primary completion date: October 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

All of the following criteria must be met to randomize a subject in the study:

1. Subjects must be competent to understand the information given in the Independent Ethics Committee (IEC) or Institutional Review Board (IRB) approved informed consent form and must sign and date the informed consent prior to any study mandated procedure

2. Subjects must be willing and able to comply with study requirements

3. Age = 18 years

4. Subjects must have a confirmed diagnosis of IBD (endoscopic and/or biopsy)

5. Subjects must be considered suitable for intravenous iron treatment by the Investigator

6. Subjects must have iron deficiency anaemia defined by the following criteria:

1. Hb 8.0 g/dL and =11.0 g/dL for women OR a Hb 8.0 g/dL and =12.0 g/dL for men

2. AND Ferritin <30ng/ml OR Ferritin <100 ng/ml WITH Transferrin saturation (TSAT) <20%

7. Female subjects of childbearing potential (including perimenopausal females who have had a menstrual period within 1 year prior to screening) must agree to use a reliable method of contraception until they have completed the study and for at least 4 weeks following their final study visit. Reliable contraception is defined as a method which results in a low failure rate, i.e., less than 1% per year when used consistently and correctly, such as implants, injectables, some intrauterine contraceptive devices (IUDs), complete sexual abstinence, or a vasectomized partner. Oral contraceptive medications are allowed in this study. Female subjects who are surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy) or postmenopausal (defined as no menstrual period within 1 year of screening) are also allowed to participate.

A subject who meets any of the following criteria is not eligible for participation in the study.

1. Subject with anaemia due to any cause other than iron deficiency, including, but not limited to:

1. Untreated or untreatable severe malabsorption syndrome

2. Immunosuppressant use. Immunosuppressants are permitted so long as there is no clinical evidence or suspicion of the immunosuppressant contributing to the subject's anaemia or affecting erythropoiesis.

Variations to dosing are permitted at the discretion of the investigator so long as there is no clinical evidence or suspicion of the immunosuppressant contributing to the subject's anaemia or affecting erythropoiesis

2. Subject who has received prior to screening:

1. Within 8 weeks intramuscular or intravenous (IV) iron or administration of depot iron preparation

2. Within 2 weeks a blood transfusion

3. Oral iron supplementation, taken specifically to treat anaemia, within the previous 4 weeks (Over the Counter (OTC) multivitamins containing iron are permitted)

3. Subjects with active inflammatory bowel disease as defined by a SCCAI score greater than 5 at Screening or a CDAI score greater than 300 in the Screening period (as assessed using the Screening haematocrit (HCT) and CDAI diary card completed by the subject for 7 days prior to planned randomization).

4. Subjects with known hypersensitivity or allergy to either the active substance or excipients of ferric maltol capsules or ferric carboxymaltose solution for IV administration

5. Subjects who have had serious adverse reactions to previous doses of ferric carboxymaltose or any other intravenous iron.

6. Subjects with contraindication for treatment with iron preparations, e.g. hemochromatosis, chronic hemolytic disease, sideroblastic anaemia, thalassemia, or lead intoxication induced anaemia.

7. Subjects with vitamin B12 or folic acid deficiency as determined by the central laboratory screening results. Subjects may start vitamin B12 or folate replacement and rescreen after at least 2 weeks.

8. Subjects who are pregnant or breast feeding.

9. Concomitant medical conditions with significant active bleeding likely to initiate or prolong anaemia.

10. Participation in any other interventional clinical study within 30 days prior to screening.

11. Subject with cardiovascular, liver, renal, haematologic, gastrointestinal, immunologic, endocrine, metabolic, or central nervous system disease that, in the opinion of the Investigator, may adversely affect the safety of the subject or severely limit the lifespan of the subject (i.e. unlikely to complete the full duration of the study).

12. Subject with significant neurologic or psychiatric symptoms resulting in disorientation, memory impairment, or inability to report accurately that might interfere with treatment compliance, study conduct or interpretation of the results (e.g., Alzheimer's disease, schizophrenia or other psychosis, active or current alcohol or drug abuse)

13. Subject who is an inmate of a psychiatric ward, prison, or other state institution.

14. Subject who is an Investigator or any other team member involved directly or indirectly in the conduct of the clinical study.

15. Subjects with severe renal impairment: creatinine clearance <30 mL/min. (Applicable to US sites Only)

Related Conditions & MeSH terms

• Anemia
• Anemia, Iron-Deficiency
• Crohn Disease
• Crohn's Disease
• Inflammatory Bowel Disease
• Inflammatory Bowel Diseases
• Intestinal Diseases

Intervention

Drug:
• Ferric Maltol

• Ferric Carboxy Maltose

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Shield Therapeutics

Countries where clinical trial is conducted

United States,  Belgium,  France,  Germany,  Hungary,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Change From Baseline Physical Component and Mental Component Score	A multipurpose, proprietary health survey with 36 questions. It was constructed to survey health status in the Medical Outcomes Study and designed for use in clinical practice and research & general population surveys.; The SF-36 includes one multi-item scale that assesses 8 health components: Physical Functioning Component; Social Functioning Component; Role-Physical Component; Bodily Pain Component; Mental Health Component; Role-Emotional Component; Vitality Component; & General Health Component.; These 8 health component scales can be further summarised into 2 summary scores, the Mental Component Score & the Physical Component Score where higher values mean a better outcome.; Both scales range from 0 to 100, where higher scores indicate better health status.; The survey will be administered at study visits as indicated in the schedule of assessments, commencing pre-randomization at Visit 2. The survey will be completed by the subjects in their native language.	Baseline to Week 52 (LOCF)
Other	Number of Patients With Treatment-emergent Adverse Events (AEs)	Number of Patients with Treatment-emergent Adverse Events (AEs).	Baseline to Week 52
Other	Number of Patients With Treatment-emergent Serious Adverse Events (SAEs)	Number of Patients with Treatment-emergent Serious Adverse Events (SAEs).	Baseline to Week 52
Primary	Number of Subjects Achieving Either a 2g/dL Increase in Hb OR Normalization of Hb at Week 12	Number of subjects achieving either a 2g/dL increase in Hb OR normalization of Hb (>=12g/dL women,>=13g/dL men) at Week 12	Baseline to Week 12
Primary	Number of Subjects Achieving Either a 2g/dL Increase in Hb OR Normalization of Hb at Week 12	Number of subjects achieving either a 2g/dL increase in Hb OR normalization of Hb (>=12g/dL women, >=13g/dL men) at Week 12	Baseline to Week 12
Secondary	Change in Hb Concentration From Baseline to Week 12	Change in hemoglobin concentration from baseline to Week 12.	Baseline to Week 12
Secondary	Change in Hb Concentration From Baseline to Week 12 in Subjects With a Baseline Hb <9.5 g/dL	Change in hemoglobin concentration from baseline to Week 12 in subjects with a baseline hemoglobin <9.5 g/dL.	Baseline to Week 12
Secondary	Number of Subjects Who Experience a Change From Baseline in Hb Concentration =1.0 g/dL at Week 12	Number of subjects who experience a change from baseline in hemoglobin concentration =1.0 g/dL at Week 12.	Baseline to Week 12
Secondary	Number of Subjects With Baseline Hb <9.5g/dL That Achieve an Increase in Hb Concentration of =1 g/dL at Week 12	Number of subjects with baseline hemoglobin <9.5g/dL that achieve an increase in hemoglobin concentration of =1 g/dL at Week 12.	Baseline to Week 12
Secondary	Number of Subjects With Hb Concentration Within Normal Limits at Week 12	Number of subjects with Hb concentration within normal limits at Week 12 (normal limit definition: >=12g/dL women, >=13g/dL men)	Baseline to Week 12
Secondary	Number of Subjects With Baseline Hb Concentration <9.5 g/dL That is Within Normal Limits at Week 12	Number of subjects with baseline Hb concentration <9.5 g/dL that is within normal limits at Week 12 (normal limit definition: >=12g/dL women, >=13g/dL men)	Baseline to Week 12
Secondary	Proportion of Subjects Who Are Non-anaemic at 6 Months and 12 Months	Long term efficacy endpoints i.e. proportion of subjects who are non-anaemic at 6 months and 12 months (normal limit definition: >=12g/dL women, >=13g/dL men)	Baseline to Month 6
Secondary	Change in Hb Concentration From Baseline to Week 4	Change in hemoglobin concentration from baseline to Week 4.	Baseline to Week 4
Secondary	Change in Hb Concentration From Baseline to Week 4 in Subjects With a Baseline Hb <9.5 g/dL	Change in hemoglobin concentration from baseline to Week 4 in subjects with a baseline hemoglobin <9.5 g/dL.	Baseline to Week 4
Secondary	Number of Subjects Who Experience a Change From Baseline in Hb Concentration =2.0 g/dL at Week 12	Number of subjects who experience a change from baseline in hemoglobin concentration =2.0 g/dL at Week 12.	Baseline to Week 12
Secondary	Number of Subjects With Baseline Hb <9.5g/dL That Achieve an Increase in Hb Concentration of =2 g/dL at Week 12	Number of subjects with baseline hemoglobin <9.5g/dL that achieve an increase in hemoglobin concentration of =2 g/dL at Week 12.	Baseline to Week 12
Secondary	Number of Subjects Who Experience a Change From Baseline in Hb Concentration =1.0 g/dL at Week 4	Number of subjects who experience a change from baseline in hemoglobin concentration =1.0 g/dL at Week 4.	Baseline to Week 4
Secondary	Number of Subjects With Baseline Hb <9.5g/dL That Achieve an Increase in Hb Concentration of =1 g/dL at Week 4	Number of subjects with baseline hemoglobin <9.5g/dL that achieve an increase in hemoglobin concentration of =1 g/dL at Week 4.	Baseline to Week 4
Secondary	Number of Subjects With Hb Concentration Within Normal Limits at Week 4	Number of subjects with Hb concentration within normal limits at Week 4 (normal limit definition: >=12g/dL women, >=13g/dL men)	Baseline to Week 4
Secondary	Number of Subjects With Baseline Hb Concentration <9.5 g/dL That is Within Normal Limits at Week 4	Number of subjects with baseline Hb concentration <9.5 g/dL that is within normal limits at Week 4 (normal limit definition: >=12g/dL women, >=13g/dL men)	Baseline to Week 4
Secondary	Number of Subjects Who Experience a Change From Baseline in Hb Concentration =2.0 g/dL at Week 4	Number of subjects who experience a change from baseline in hemoglobin concentration =2.0 g/dL at Week 4.	Baseline to Week 4
Secondary	Number of Subjects With Baseline Hb <9.5g/dL That Achieve an Increase in Hb Concentration of =2 g/dL at Week 4	Number of subjects with baseline hemoglobin <9.5g/dL that achieve an increase in hemoglobin concentration of =2 g/dL at Week 4	Baseline to Week 4